Methods of treating cancer using bacteria expressing c-di-AMP
AssigneeThe Johns Hopkins University
InventorsWilliam R. Bishai, Ruchi Jain Dey, Bappaditya Dey, Laurene Cheung
Life of this patent
Estimating the term…
Abstract
The present invention includes the discovery of a strain of Mycobacterium comprising an expression vector encoding a di-adenylate cyclase enzyme. The Mycobacterium is selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium bovis, or a combination thereof and the preferred strain of Mycobacterium is BCG. The preferred expression vector is a mycobacterial expression vector including an hsp60 promoter and a DNA sequence of diadenylate cyclase (disA), or a functional part thereof. The strains of Mycobacterium are used in therapeutic applications including tuberculosis and cancer.
Claims39
A pharmaceutical composition comprising:
- (i) a recombinant Mycobacterium comprising a Mycobacterium from a first strain comprising an expression vector encoding a di-adenylate cyclase enzyme from a second strain of Mycobacterium, and
- (ii) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (i) a recombinant Mycobacterium comprising a Mycobacterium from a first strain comprising an expression vector encoding a di-adenylate cyclase enzyme from a second strain of Mycobacterium,
- (ii) at least one compounds enhancing immunogenicity, and
- (iii) a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising:
- (i) a recombinant Mycobacterium comprising a Mycobacterium bovis Bacille Calmette Guerin (BCG) comprising an expression vector encoding a di-adenylate cyclase enzyme from Mycobacterium tuberculosis, and
- (ii) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.